Syndetics cover image
Image from Syndetics

Merck & Company, Inc. : the recall of Vioxx (B) / Andrew M. Gust, Grant D. Bartucci, James S. O'Rourke.

By: Contributor(s): Material type: TextSeries: Publisher: London : SAGE Publications Ltd, 2017Description: 1 online resourceContent type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781526406392 (ebook) :
Other title:
  • Merck and Company, Inc
Subject(s): DDC classification:
  • 338.4761699406
Online resources: Influenced by the preliminary results of an internal clinical trial, Raymond Gilmartin, CEO of Merck, announced that the company was pulling its blockbuster arthritis drug Vioxx from the worldwide market on September 30, 2004. Merck & Company, Inc., once the worlds largest pharmaceutical company, saw its stock price plummet 27% after the recall announcement. Facing recent sales declines, a barrage of lawsuits, and two separate government investigations, Merck is losing its once-stellar reputation in the pharmaceutical industry.
No physical items for this record

Originally published: Gust, A. M., Bartucci, G. D., & ORourke, J. S. (2005). Merck & Company, Inc.: The recall of Vioxx (B). 05-01 (B). Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.

Influenced by the preliminary results of an internal clinical trial, Raymond Gilmartin, CEO of Merck, announced that the company was pulling its blockbuster arthritis drug Vioxx from the worldwide market on September 30, 2004. Merck & Company, Inc., once the worlds largest pharmaceutical company, saw its stock price plummet 27% after the recall announcement. Facing recent sales declines, a barrage of lawsuits, and two separate government investigations, Merck is losing its once-stellar reputation in the pharmaceutical industry.

Description based on XML content.

Licensed e-book